EMA restricts use of Pembrolizumab and Atezolizumab in bladder cancer

June 1, 2018 – Early data from two clinical trials1 show reduced survival with Pembrolizumab and Atezolizumab when used as first-line treatments for urothelial cancer (cancer of the bladder and urinary tract) in patients with low levels of a protein called PD-L1. The data indicate that Pembrolizumab and Atezolizumab may not work as well as chemotherapy medicines in this group of patients. As a result, the European Medicines Agency (EMA) has recommended restricting the use of these … (leggi tutto)